{
    "organizations": [],
    "uuid": "5d47fe6dc70e6946ebce8187caad9c0e8fcb7212",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-acelrx-pharmaceuticals-reports-q1/brief-acelrx-pharmaceuticals-reports-q1-loss-per-share-0-23-idUSASC0A13S",
    "ord_in_thread": 0,
    "title": "BRIEF-AcelRx Pharmaceuticals Reports Q1 Loss Per Share $0.23",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 9 (Reuters) - AcelRx Pharmaceuticals Inc:\n* ACELRX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 LOSS PER SHARE $0.23 * Q1 EARNINGS PER SHARE VIEW $-0.24 â€” THOMSON REUTERS I/B/E/S\n* EXPECTED ACCEPTANCE OF DSUVIA NDA BY FDA IN Q2 2018 * POTENTIAL EUROPEAN COMMISSION APPROVAL OF DZUVEO IN Q3 2018\n* MARCH 31, 2018 CASH AND SHORT-TERM INVESTMENTS BALANCE OF $51.2 MILLION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-10T04:47:00.000+03:00",
    "crawled": "2018-05-10T17:36:13.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "acelrx",
        "pharmaceutical",
        "inc",
        "acelrx",
        "pharmaceutical",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "expected",
        "acceptance",
        "dsuvia",
        "nda",
        "fda",
        "q2",
        "potential",
        "european",
        "commission",
        "approval",
        "dzuveo",
        "q3",
        "march",
        "cash",
        "investment",
        "balance",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}